Disc Medicine FY2024 EPS Estimate Raised by HC Wainwright

Disc Medicine, Inc. (NASDAQ:IRON) – HC Wainwright upped their FY2024 earnings per share estimates for shares of Disc Medicine in a report issued on Wednesday, November 13th. HC Wainwright analyst D. Tsao now anticipates that the company will earn ($3.88) per share for the year, up from their prior forecast of ($3.91). HC Wainwright has a “Buy” rating and a $118.00 price objective on the stock. The consensus estimate for Disc Medicine’s current full-year earnings is ($4.15) per share. HC Wainwright also issued estimates for Disc Medicine’s Q4 2024 earnings at ($0.88) EPS, Q1 2025 earnings at ($1.02) EPS, Q2 2025 earnings at ($1.17) EPS, Q3 2025 earnings at ($1.33) EPS, Q4 2025 earnings at ($1.35) EPS, FY2025 earnings at ($4.87) EPS, FY2026 earnings at ($3.94) EPS, FY2027 earnings at ($3.38) EPS and FY2028 earnings at ($1.50) EPS.

A number of other equities research analysts also recently weighed in on IRON. Jefferies Financial Group initiated coverage on Disc Medicine in a research report on Wednesday, October 23rd. They set a “buy” rating and a $89.00 price target on the stock. Raymond James raised Disc Medicine from an “outperform” rating to a “strong-buy” rating and raised their price objective for the company from $66.00 to $110.00 in a report on Monday, November 4th. Scotiabank upped their target price on Disc Medicine from $62.00 to $70.00 and gave the stock a “sector outperform” rating in a research note on Tuesday, November 5th. Wedbush restated an “outperform” rating and issued a $83.00 price objective (up from $75.00) on shares of Disc Medicine in a report on Tuesday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $85.00 price objective on shares of Disc Medicine in a research note on Tuesday, October 15th. Nine analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Disc Medicine currently has a consensus rating of “Buy” and an average price target of $85.80.

Disc Medicine Stock Performance

Disc Medicine stock opened at $59.46 on Friday. Disc Medicine has a fifty-two week low of $25.60 and a fifty-two week high of $77.60. The stock has a market cap of $1.77 billion, a P/E ratio of -14.94 and a beta of 0.60. The firm’s fifty day moving average price is $51.20 and its 200-day moving average price is $44.97.

Disc Medicine (NASDAQ:IRON) last announced its earnings results on Tuesday, November 12th. The company reported ($0.89) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.04) by $0.15.

Institutional Investors Weigh In On Disc Medicine

A number of large investors have recently made changes to their positions in the business. Amalgamated Bank lifted its stake in Disc Medicine by 76.9% in the second quarter. Amalgamated Bank now owns 568 shares of the company’s stock worth $26,000 after acquiring an additional 247 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in Disc Medicine by 45.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company’s stock valued at $54,000 after purchasing an additional 337 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Disc Medicine in the 2nd quarter worth $129,000. Quest Partners LLC purchased a new stake in shares of Disc Medicine in the 3rd quarter worth about $131,000. Finally, Quantbot Technologies LP bought a new stake in shares of Disc Medicine during the 3rd quarter valued at about $146,000. 83.70% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Disc Medicine news, Director William Richard White sold 7,136 shares of the company’s stock in a transaction that occurred on Monday, November 4th. The stock was sold at an average price of $58.61, for a total transaction of $418,240.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold a total of 7,538 shares of company stock valued at $437,875 in the last quarter. Insiders own 4.24% of the company’s stock.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.